FI955429A7 - 1-aryylisykloalkyylisulfideja, sulfoksideja ja sulfoneja depression, t uskatilojen ja Parkinsonin taudin hoitamiseksi - Google Patents

1-aryylisykloalkyylisulfideja, sulfoksideja ja sulfoneja depression, t uskatilojen ja Parkinsonin taudin hoitamiseksi Download PDF

Info

Publication number
FI955429A7
FI955429A7 FI955429A FI955429A FI955429A7 FI 955429 A7 FI955429 A7 FI 955429A7 FI 955429 A FI955429 A FI 955429A FI 955429 A FI955429 A FI 955429A FI 955429 A7 FI955429 A7 FI 955429A7
Authority
FI
Finland
Prior art keywords
arylcycloalkyl
sulfoxides
sulfones
sulfides
parkinson
Prior art date
Application number
FI955429A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI955429L (fi
FI955429A0 (fi
Inventor
Paul John Harris
David John Heal
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of FI955429A0 publication Critical patent/FI955429A0/fi
Publication of FI955429L publication Critical patent/FI955429L/fi
Publication of FI955429A7 publication Critical patent/FI955429A7/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/26Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/04Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FI955429A 1993-05-12 1994-05-07 1-aryylisykloalkyylisulfideja, sulfoksideja ja sulfoneja depression, t uskatilojen ja Parkinsonin taudin hoitamiseksi FI955429A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939309749A GB9309749D0 (en) 1993-05-12 1993-05-12 Therapeutic agents
PCT/EP1994/001494 WO1994026704A1 (en) 1993-05-12 1994-05-07 1-arylcycloalkyl sulphides, sulphoxides and sulphones for the treatment of depression, anxiety and parkinson's disease

Publications (3)

Publication Number Publication Date
FI955429A0 FI955429A0 (fi) 1995-11-10
FI955429L FI955429L (fi) 1996-01-03
FI955429A7 true FI955429A7 (fi) 1996-01-03

Family

ID=10735317

Family Applications (1)

Application Number Title Priority Date Filing Date
FI955429A FI955429A7 (fi) 1993-05-12 1994-05-07 1-aryylisykloalkyylisulfideja, sulfoksideja ja sulfoneja depression, t uskatilojen ja Parkinsonin taudin hoitamiseksi

Country Status (29)

Country Link
US (1) US5652271A (enExample)
EP (1) EP0715620B1 (enExample)
JP (2) JP3606326B2 (enExample)
KR (1) KR100295264B1 (enExample)
AT (1) ATE172719T1 (enExample)
AU (1) AU681669B2 (enExample)
BG (1) BG61913B1 (enExample)
BR (2) BR9406577A (enExample)
CZ (1) CZ290711B6 (enExample)
DE (1) DE69414264T2 (enExample)
DK (1) DK0715620T3 (enExample)
ES (1) ES2124411T3 (enExample)
FI (1) FI955429A7 (enExample)
GB (1) GB9309749D0 (enExample)
HU (1) HU211124A9 (enExample)
IL (1) IL109635A (enExample)
LV (1) LV11320A (enExample)
MY (1) MY110773A (enExample)
NO (1) NO305165B1 (enExample)
NZ (1) NZ266776A (enExample)
PH (1) PH30418A (enExample)
PL (1) PL176400B1 (enExample)
RO (1) RO115519B1 (enExample)
RU (1) RU2135467C1 (enExample)
SK (1) SK281257B6 (enExample)
TW (1) TW318833B (enExample)
UA (1) UA42722C2 (enExample)
WO (1) WO1994026704A1 (enExample)
ZA (1) ZA943241B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19518988A1 (de) * 1995-05-29 1996-12-05 Basf Ag Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
GB9524681D0 (en) 1995-12-02 1996-01-31 Knoll Ag Chemical process
GB9915617D0 (en) * 1999-07-05 1999-09-01 Knoll Ag Therapeutic agents
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
PL2011796T3 (pl) * 2006-04-26 2015-03-31 Toyama Chemical Co Ltd Induktor neurogenezy lub środek terapeutyczny do stosowania w neuropatii zawierający pochodną eteru alkilowego lub jej sól
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
ES2823000T3 (es) 2013-10-07 2021-05-05 Impax Laboratories Llc Formulaciones muco-adhesivas de liberación controlada de levodopa y/o ésteres de levodopa y usos de las mismas
JP2024501235A (ja) 2020-12-22 2024-01-11 アムニール ファーマスーティカルズ エルエルシー レボドパ投薬レジメン
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
IE56000B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylalkylamine compounds
IE56001B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylmethylamine compounds
GB8501192D0 (en) * 1985-01-17 1985-02-20 Boots Co Plc Therapeutic agents
CH664957A5 (de) * 1985-09-24 1988-04-15 Lonza Ag Verfahren zur herstellung von 4-hydroxy-2-oxo-pyrrolidin-1-yl-acetamid.
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment

Also Published As

Publication number Publication date
ATE172719T1 (de) 1998-11-15
FI955429L (fi) 1996-01-03
PH30418A (en) 1997-05-09
MY110773A (en) 1999-03-31
JPH08510222A (ja) 1996-10-29
BR1100306A (pt) 2002-04-02
CZ290711B6 (cs) 2002-09-11
BG61913B1 (bg) 1998-09-30
PL311628A1 (en) 1996-03-04
JP3606326B2 (ja) 2005-01-05
CZ293695A3 (en) 1996-06-12
EP0715620B1 (en) 1998-10-28
GB9309749D0 (en) 1993-06-23
UA42722C2 (uk) 2001-11-15
NO954542D0 (no) 1995-11-10
DE69414264D1 (de) 1998-12-03
WO1994026704A1 (en) 1994-11-24
US5652271A (en) 1997-07-29
BG100127A (bg) 1996-07-31
KR100295264B1 (ko) 2001-09-17
RO115519B1 (ro) 2000-03-30
IL109635A0 (en) 1994-11-11
PL176400B1 (pl) 1999-05-31
HU211124A9 (en) 1995-10-30
NO954542L (no) 1996-01-10
NZ266776A (en) 1998-02-26
SK140795A3 (en) 1996-09-04
LV11320A (lv) 1996-06-20
ZA943241B (en) 1994-11-14
FI955429A0 (fi) 1995-11-10
DE69414264T2 (de) 1999-03-25
SK281257B6 (sk) 2001-01-18
TW318833B (enExample) 1997-11-01
ES2124411T3 (es) 1999-02-01
EP0715620A1 (en) 1996-06-12
RU2135467C1 (ru) 1999-08-27
IL109635A (en) 1998-03-10
AU681669B2 (en) 1997-09-04
JP2004331669A (ja) 2004-11-25
AU6843394A (en) 1994-12-12
NO305165B1 (no) 1999-04-12
BR9406577A (pt) 1996-01-30
DK0715620T3 (da) 1999-07-05

Similar Documents

Publication Publication Date Title
HUP9800033A3 (en) Compositions for the treatment of dermatological disorders and methods for their use
NO992755D0 (no) Protese for °yets senehinne for behandling av presbyopi og andre forstyrrelser i °yner
DE69828892D1 (de) Verwendung von uridin-5'-diphosphat und analoge zur behandlung von lungenerkrankungen
SG100766A1 (en) Sulfonamides for treatment of endothelin-mediated disorders
ITFI910071U1 (it) Piastra per osso per la porzione distale dell'omero.
EP0331620A3 (en) Agent for the treatment of parkinson's disease
FI955429A7 (fi) 1-aryylisykloalkyylisulfideja, sulfoksideja ja sulfoneja depression, t uskatilojen ja Parkinsonin taudin hoitamiseksi
BR9707922A (pt) Cafeína e clemastina para tratamento de distúrbios respiratórios
IT9041529A0 (it) Dispositivo per la correzione chirurgica dell'ametropia
AU4131296A (en) Treatment of disorders with duloxetine
BR9507980A (pt) Composto composição farmacêutica para uso no tratamento e/ou profilaxia de ansiedade mania depressão desordens associadas com uma hemorragia subaracnóide ou choke neural processo de tratamento e/ou profilaxia de ansiedade mania depressão desordens associadas com uma hemorragia subaracnóide ou choque neural composição farmacêutica uso de um composto
AU3364499A (en) Method for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
US4931457B1 (en) Naphthylamino-and naphthyloxy-pyridineamin compounds useful as topical antiinflammatory agents for the treatment of skin disorders
BR9612074A (pt) Novos 4-(1h-benzimidazol-2-il)(1,4) diazepanos substituidos úteis para o tratamento de doenças alérgicas
IT1288399B1 (it) Medicamento per il trattamento terapeutico della maculopatia legata all'eta', della maculopatia non legata all'eta' e per la profilassi
HUP0000785A3 (en) Ointment for the treatment of burns and other skin diseases
AU6678194A (en) Agents for the prevention and treatment of huntington's disease and other neurological disorders
FI952953L (fi) Aineita metabolisten luustosairauksien hoitamiseen
AU7622798A (en) Application of thalidomide to the treatment of Parkinson's disease and Parkisonian syndromes
ITRM940806A0 (it) Preparato per il trattamento dell'obesita'
SE8802323L (sv) 8alfa-acylaminoergolin, dess framstaellning samt farmaceutiska kompositioner innehaallande detsamma
ITMI931371A1 (it) Procedimento per la preparazione dell'erdosteina
ITRM970235A0 (it) Catetere per la diagnosi e il trattamento dell'eiaculazione precoce
KR960700729A (ko) 26,26,26,27,27,27-헥사플루오로-1 알파, 25-디히드록시콜레칼시페롤의 칼슘 대사 장애의 치료 용도(Use of 26,26,26,27,27,27-Hexafluoro-1alpha, 25-Dihydroxycholecalciferol for the treatment of Calcium Metabolism Disorders)
ITFI930001A0 (it) Medicamento per il trattamento dell'asma.